The Impact of Orlistat on Diabetic Patients Experiencing Overweight and Constipation: A Randomized Clinical Trial

Zabihi, Mohsen; Naseri, Fatemeh; Ghanei, Azam

doi:10.18502/ijdo.v17i3.19263

Volume 17, Issue 3 (7-2025) IJDO 2025, 17(3): 150-158 | Back to browse issues page

‎ 10.18502/ijdo.v17i3.19263

Mendeley

Zotero

RefWorks

Zabihi M, Naseri F, Ghanei A. The Impact of Orlistat on Diabetic Patients Experiencing Overweight and Constipation: A Randomized Clinical Trial. IJDO 2025; 17 (3) :150-158
URL: http://ijdo.ssu.ac.ir/article-1-963-en.html

The Impact of Orlistat on Diabetic Patients Experiencing Overweight and Constipation: A Randomized Clinical Trial

Mohsen Zabihi

, Fatemeh Naseri

, Azam Ghanei ^*

Department of Internal Medicine, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Abstract: (22 Views)

Objective: Obesity is a global health concern, the use of Orlistat as an anti-obesity drug, has shown promise in managing the constipation and blood sugar levels in diabetic patients. This study aimed to evaluate the impact of Orlistat on diabetic patients experiencing both overweight and constipation.
Materials and Methods: A total of 80 overweight and constipated diabetic patients were randomly enrolled. Participants were randomly assigned to either the intervention or control group. The intervention group received 120 mg Orlistat with lunch for three months, while the control group received placebo, taken once daily with lunch for the same duration. Clinical and paraclinical parameters, including body mass index (BMI), constipation, fasting blood sugar (FBS), HbA1C, triglycerides (TG), cholesterol (CHL), high-density lipoprotein (HDL), creatinine (Cr), aspartate transaminase (AST), alanine transaminase (ALT), and blood sugar two hours postprandial (BS-2HPP), were assessed before and after the intervention.
Results: Significantly, the BS-2HPP and ALT decreased in the interventiom group. Additionally, there was a noteworthy improvement in constipation within the intervention group compared to the control group.
Conclusion: Orlistat demonstrates some effectiveness in improving clinical parameters in diabetic patients with obesity and constipation. While the drug shows notable efficacy in alleviating constipation, its impact on other related parameters is not statistically significant. No significant side effects were observed with Orlistat.

Keywords: Diabetes mellitus, Orlistat, Constipation, Obesity, Clinical trial

Full-Text [PDF 729 kb] (10 Downloads)

Type of Study: Research | Subject: Special
Received: 2025/03/27 | Accepted: 2025/06/9 | Published: 2025/07/28

References

1. Shukla A, Kumar K, Singh A. Association between obesity and selected morbidities: a study of BRICS countries. PloS one. 2014 Apr 9;9(4):e9443.

2. Cabrera-Fuentes HA, Aragones J, Bernhagen J, Boening A, Boisvert WA, Bøtker HE, et al. From basic mechanisms to clinical applications in heart protection, new players in cardiovascular diseases and cardiac theranostics: meeting report from the third international symposium on "New frontiers in cardiovascular research". Basic research in cardiology. 2016;111(6):69.

3. Cabrera-Fuentes HA, Alba-Alba C, Aragones J, Bernhagen J, Boisvert WA, Bøtker HE, et al. Meeting report from the 2nd International Symposium on New Frontiers in Cardiovascular Research. Protecting the cardiovascular system from ischemia: between bench and bedside. Basic research in cardiology. 2016;111(7):1-3.

4. Romero-Corral A, Somers VK, Sierra-Johnson J, Thomas RJ, Collazo-Clavell ML, Korinek JE, et al. Accuracy of body mass index in diagnosing obesity in the adult general population. International journal of obesity. 2008;32(6):959-66.

5. Bray GA. Evaluation of obesity: who are the obese?. Postgraduate medicine. 2003;114(6):19-38.

6. Purnamasari D, Badarsono S, Moersadik N, Sukardji K, Tahapary DL. Identification, evaluation and treatment of overweight and obesity in adults: Clinical practice guidelines of the obesity clinic, Wellness Cluster Cipto Mangunkusumo Hospital, Jakarta, Indonesia. Journal of the ASEAN Federation of Endocrine Societies. 2011;26(2):117. [DOI:10.15605/jafes.026.2.06]

7. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: a critical review. Drug safety. 2008;31:53-65.

9. Rodriquez IM, O'Sullivan KL. Youth-onset type 2 diabetes: burden of complications and socioeconomic cost. Current diabetes reports. 2023;23(5):59-67.

10. Ekpor E, Akyirem S, Adade Duodu P. Prevalence and associated factors of overweight and obesity among persons with type 2 diabetes in Africa: a systematic review and meta-analysis. Annals of medicine. 2023;55(1):696-713.

11. Shibib L, Al-Qaisi M, Ahmed A, Miras AD, Nott D, Pelling M, Greenwald SE, Guess N. Reversal and remission of t2dm-an update for practitioners. Vascular Health and Risk Management. 2022:417-43.

12. Levin A, Kaur N, Mainoo NK, Perez A. prevalence of antiobesity treatment and weight-inducing antihyperglycemic agents among patients with type 2 diabetes in the United States. Clinical Therapeutics. 2022;44(3):e35-44.

13. Minuto N, Bassi M, Montobbio C, Vinci F, Mercuri C, Perri FN, et al. The effect of lockdown and physical activity on glycemic control in Italian children and young patients with type 1 diabetes. Frontiers in endocrinology. 2021;12:690222.

14. Paulweber B, Valensi P, Lindström J, Lalic NM, Greaves CJ, McKee M, et al. A European evidence-based guideline for the prevention of type 2 diabetes. Hormone and Metabolic research. 2010;42(S 01):S3-6.

15. Dimidi E, Christodoulides S, Scott SM, Whelan K. Mechanisms of action of probiotics and the gastrointestinal microbiota on gut motility and constipation. Advances in nutrition. 2017;8(3):484-94.

16. Ballinger A, Peikin SR. Orlistat: its current status as an anti-obesity drug. European journal of pharmacology. 2002;440(2-3):109-17.

17. Feinle C, Rades T, Otto B, Fried M. Fat digestion modulates gastrointestinal sensations induced by gastric distention and duodenal lipid in humans. Gastroenterology. 2001;120(5):1100-7.

18. Packard KA, Wurdeman RL, Reyes AP. Constipation, polyuria, polydipsia, and edema associated with orlistat. Annals of Pharmacotherapy. 2002;36(7-8):1168-70.

19. Heck AM, Calis KA, McDuffie JR, Carobene SE, Yanovski JA. Additive gastrointestinal effects with concomitant use of olestra and orlistat. Annals of Pharmacotherapy. 2002;36(6):1003-5.

20. Axon E, Atkinson G, Richter B, Metzendorf MI, Baur L, Finer N, Corpeleijn E, O'Malley C, Ells LJ, Cochrane Metabolic and Endocrine Disorders Group. Drug interventions for the treatment of obesity in children and adolescents. Cochrane Database of Systematic Reviews. 2016;11(11):CD012436.

21. Patni N, Quittner C, Garg A. Orlistat therapy for children with type 1 hyperlipoproteinemia: a randomized clinical trial. The Journal of Clinical Endocrinology & Metabolism. 2018;103(6):2403-7.

22. Song J, Ruan X, Gu M, Wang L, Wang H, Mueck AO. Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. Gynecological Endocrinology. 2018;34(5):413-7.

23. Holmbäck U, Forslund A, Grudén S, Alderborn G, Söderhäll A, Hellström PM, et al. Effects of a novel combination of orlistat and acarbose on tolerability, appetite, and glucose metabolism in persons with obesity. Obesity science & practice. 2020;6(3):313-23.

24. Jarrett ZS, Chung-ting JK, Wan W, Colburn JA. The use of orlistat in an adult with lipoprotein lipase deficiency: a case report. AACE Clinical Case Reports. 2022;8(2):93-5.

25. Aldekhail NM, Logue J, McLoone P, Morrison DS. Effect of orlistat on glycaemic control in overweight and obese patients with type 2 diabetes mellitus: a systematic review and meta‐analysis of randomized controlled trials. Obesity reviews. 2015;16(12):1071-80.

26. Derosa G, Cicero AF, D'Angelo A, Fogari E, Maffioli P. Effects of 1‐year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes. Journal of clinical pharmacy and therapeutics. 2012;37(2):187-95.

27. Derosa G, Maffioli P, Ferrari I, D'Angelo A, Fogari E, Palumbo I, et al. Comparison between orlistat plus l‐carnitine and orlistat alone on inflammation parameters in obese diabetic patients. Fundamental & clinical pharmacology. 2011;25(5):642-51.